121 related articles for article (PubMed ID: 31588852)
21. μ-Opioid receptor 6-transmembrane isoform: A potential therapeutic target for new effective opioids.
Convertino M; Samoshkin A; Gauthier J; Gold MS; Maixner W; Dokholyan NV; Diatchenko L
Prog Neuropsychopharmacol Biol Psychiatry; 2015 Oct; 62():61-7. PubMed ID: 25485963
[TBL] [Abstract][Full Text] [Related]
22. Structural and functional analysis of ProQ: an osmoregulatory protein of Escherichia coli.
Smith MN; Kwok SC; Hodges RS; Wood JM
Biochemistry; 2007 Mar; 46(11):3084-95. PubMed ID: 17319698
[TBL] [Abstract][Full Text] [Related]
23. Purification and mass spectrometric analysis of the mu opioid receptor.
Christoffers KH; Li H; Keenan SM; Howells RD
Brain Res Mol Brain Res; 2003 Oct; 118(1-2):119-31. PubMed ID: 14559361
[TBL] [Abstract][Full Text] [Related]
24. Engineering and functional immobilization of opioid receptors.
Ott D; Neldner Y; Cèbe R; Dodevski I; Plückthun A
Protein Eng Des Sel; 2005 Mar; 18(3):153-60. PubMed ID: 15790572
[TBL] [Abstract][Full Text] [Related]
25. Use of dual affinity tags for expression and purification of functional peripheral cannabinoid receptor.
Yeliseev A; Zoubak L; Gawrisch K
Protein Expr Purif; 2007 May; 53(1):153-63. PubMed ID: 17223358
[TBL] [Abstract][Full Text] [Related]
26. Expression and purification of soluble and functional fusion protein DAB
Zarkar N; Nasiri Khalili MA; Khodadadi S; Zeinoddini M; Ahmadpour F
Biotechnol Appl Biochem; 2020 Mar; 67(2):206-212. PubMed ID: 31600001
[TBL] [Abstract][Full Text] [Related]
27. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
[TBL] [Abstract][Full Text] [Related]
28. Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm.
Pan L; Xu J; Yu R; Xu MM; Pan YX; Pasternak GW
Neuroscience; 2005; 133(1):209-20. PubMed ID: 15893644
[TBL] [Abstract][Full Text] [Related]
29. A constitutively internalizing and recycling mutant of the mu-opioid receptor.
Segredo V; Burford NT; Lameh J; Sadée W
J Neurochem; 1997 Jun; 68(6):2395-404. PubMed ID: 9166733
[TBL] [Abstract][Full Text] [Related]
30. Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the "address" recognition locus.
Metzger TG; Paterlini MG; Ferguson DM; Portoghese PS
J Med Chem; 2001 Mar; 44(6):857-62. PubMed ID: 11300867
[TBL] [Abstract][Full Text] [Related]
31. Genomic variations and transcriptional regulation of the human mu-opioid receptor gene.
Bayerer B; Stamer U; Hoeft A; Stüber F
Eur J Pain; 2007 May; 11(4):421-7. PubMed ID: 16843022
[TBL] [Abstract][Full Text] [Related]
32. Expression and purification of SfaX(II), a protein involved in regulating adhesion and motility genes in extraintestinal pathogenic Escherichia coli.
Paracuellos P; Ohman A; Sauer-Eriksson AE; Uhlin BE
Protein Expr Purif; 2012 Dec; 86(2):127-34. PubMed ID: 23022032
[TBL] [Abstract][Full Text] [Related]
33. Structural Assessment of Agonist Efficacy in the μ-Opioid Receptor: Morphine and Fentanyl Elicit Different Activation Patterns.
Ricarte A; Dalton JAR; Giraldo J
J Chem Inf Model; 2021 Mar; 61(3):1251-1274. PubMed ID: 33448226
[TBL] [Abstract][Full Text] [Related]
34. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists.
Larson DL; Jones RM; Hjorth SA; Schwartz TW; Portoghese PS
J Med Chem; 2000 Apr; 43(8):1573-6. PubMed ID: 10780914
[TBL] [Abstract][Full Text] [Related]
35. Single-step purification of two functional human apolipoprotein E variants hyperexpressed in Escherichia coli.
Pillot T; Barbier A; Visvikis A; Lozac'h K; Rosseneu M; Vandekerckhove J; Siest G
Protein Expr Purif; 1996 Jun; 7(4):407-14. PubMed ID: 8776760
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and evaluation of a ligand targeting the μ and δ opioid receptors for drug delivery to lung cancer.
Li G; Low PS
Bioorg Med Chem Lett; 2017 May; 27(9):2074-2078. PubMed ID: 28291693
[TBL] [Abstract][Full Text] [Related]
37. QTY code designed thermostable and water-soluble chimeric chemokine receptors with tunable ligand affinity.
Qing R; Han Q; Skuhersky M; Chung H; Badr M; Schubert T; Zhang S
Proc Natl Acad Sci U S A; 2019 Dec; 116(51):25668-25676. PubMed ID: 31776256
[TBL] [Abstract][Full Text] [Related]
38. Antagonist efficacy in MORS196L mutant is affected by the interaction between transmembrane domains of the opioid receptor.
Claude-Geppert PA; Liu J; Solberg J; Erickson-Herbrandson LJ; Loh HH; Law PY
J Pharmacol Exp Ther; 2005 Apr; 313(1):216-26. PubMed ID: 15579496
[TBL] [Abstract][Full Text] [Related]
39. Isolation and expression of a novel alternatively spliced mu opioid receptor isoform, MOR-1F.
Pan YX; Xu J; Bolan E; Chang A; Mahurter L; Rossi G; Pasternak GW
FEBS Lett; 2000 Jan; 466(2-3):337-40. PubMed ID: 10682855
[TBL] [Abstract][Full Text] [Related]
40. DAMGO recognizes four residues in the third extracellular loop to discriminate between mu- and kappa-opioid receptors.
Seki T; Minami M; Nakagawa T; Ienaga Y; Morisada A; Satoh M
Eur J Pharmacol; 1998 Jun; 350(2-3):301-10. PubMed ID: 9696421
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
